JCO Oncology Practice

Hollywood's Portrayal of Cancer in Movies Fuels Misconceptions, New Study Finds

Retrieved on: 
Wednesday, January 17, 2024
Death, Patient, JCO Oncology Practice, To Kill a Mockingbird, Knowledge, Suggestion, Palliative care, Hospice, Prognosis, Cancer, Lung cancer, Immunotherapy, CDC, Oncology, Caregiver, Toxicity, Public opinion, Physician, Estate (law)

NEWPORT BEACH, Calif., Jan. 17, 2024 /PRNewswire/ -- Hollywood films may provide an unrealistic view of cancer to individuals with cancer and their families, and can create misunderstandings about curability, treatment options, types of care available and cost, according to a study published today in JCO Oncology Practice. The study was led by David J. Benjamin, M.D., a medical oncologist at Hoag in Newport Beach, California.

Key Points: 
  • "We found that the portrayals of cancer treatment, prognosis and cost of care in movies significantly diverge from reality and therefore may have an impact on how patients approach cancer care," said Dr. Benjamin.
  • The study found that the portrayal of type of cancer does not accurately reflect the most common cancers that are diagnosed.
  • Only four of the 100 movies addressed financial costs, with one focusing on the financial stresses associated with cancer treatment.
  • "Oncologists should be aware of how cancer is depicted in movies to anticipate and address potential discrepancies between patients' potential views and the reality of cancer care," the authors wrote.

JCO Oncology Practice Publishes Updated Clinical Data Demonstrating the Real-World Impact of Genomic Testing Among Patients with Stage IV, Non-Small-Cell Lung Cancer

Retrieved on: 
Monday, August 21, 2023
AOD, PALM, Non-small-cell lung cancer, Physician, OS, BRAF, TKI, National Comprehensive Cancer Network, Toxicity, Research, ERBB2, NSCLC, RWD, JCO Oncology Practice, ASCO, NCCN, South African wireless community networks, Cancer, Patient, EGFR, NTRK, Medicine, ROS1, MET, Health, Death, Society, RET, ALK, Nursing, Pharmaceutical industry

WEST PALM BEACH, Fla., Aug. 21, 2023 /PRNewswire/ -- Integra Connect, LLC., a leading provider of value-based, precision medicine solutions for specialty care, announced today that JCO Oncology Practice, an American Society of Clinical Oncology Journal, published a study that found initiating treatment prior to receiving genomic test results for actionable oncogenic drivers (AODs) in advanced non-small-cell lung cancer (NSCLC) leads to considerably inferior patient outcomes. The study's implications underscore the necessity of incorporating molecular profiling panels with rapid turnaround times as a standard of care. By doing so, healthcare professionals can optimize patient outcomes and significantly improve the effectiveness of advanced NSCLC treatments.

Key Points: 
  • The study's implications underscore the necessity of incorporating molecular profiling panels with rapid turnaround times as a standard of care.
  • By doing so, healthcare professionals can optimize patient outcomes and significantly improve the effectiveness of advanced NSCLC treatments.
  • In the real-world setting, genomic testing is highly inconsistent, and compliance with current clinical guidelines is further hampered due to slow turnaround time for receipt of molecular test results.
  • "Cancer is the second leading cause of death in the U.S. – we need to continue to research optimal treatments and put them into practice."

Canopy Publishes Research at 2023 American Society of Clinical Oncology Meeting Demonstrating the Impact of ePROs in Identifying Patients at Risk of Early Treatment Discontinuation

Retrieved on: 
Wednesday, May 31, 2023
Shadow King, Data re-identification, IO, American Society of Clinical Oncology, Clinical trial, Lung cancer, Oncology, Research, Immunotherapy, JCO Oncology Practice, ASCO, National Association Medical Staff Services, Journal, MD, Patient, Risk, Identification, Society, Medical imaging, Nursing, Pharmaceutical industry, Canopy

—Michael Kolodziej, MD

Key Points: 
  • —Michael Kolodziej, MD
    The results of the multi-site study of 172 patients were selected for online publication at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois on June 2-6, 2023.
  • The study analyzed reports submitted by lung cancer patients through Canopy's ePRO platform across three community oncology practices.
  • Enable care teams to identify at-risk patients earlier: The presence of early symptoms may indicate a patient population at high risk of early treatment discontinuation.
  • Canopy presented research at the 2022 ASCO Meeting demonstrating up to 45% higher treatment persistence and a 22% reduction in ER visits and hospitalizations for patients utilizing ePROs.